- Pfizer and BioNTech will be jointly developing BioNTech’s mRNA-based vaccine candidate BNT162 for preventing COVID-19 infection Collaboration with an aim to accelerate global development of BNT162.
- They will be leveraging expertise and resources of both companies Builds on 2018 agreement for the development of an mRNA-based influenza vaccine
Pfizer Inc., joint hands with BioNTech SE on March 17, 2020, to co-develop and distribute (excluding China) a potential mRNA-based coronavirus vaccine with an aim to prevent COVID-19 infection. The companies have executed a Material Transfer and Collaboration Agreement for immediately starting to work together.
This collaboration ai aimed at accelerating the development of BioNTech’s potential first-in-class COVID-19 mRNA vaccine program, BNT162, which by the end of April 2020, is likely to enter clinical testing. The rapid advancement of this collaboration is built on the R&D collaboration that the two companies established in 2018 for the development of mRNA-based vaccines to prevent influenza.
The companies will be utilizing multiple R&D sites from both the companies, including in the US and Germany. The companies will finalize details of the agreement regarding financial terms, and all activities related to development, manufacturing and potential commercialization over the next few weeks.
About Pfizer
Pfizer Inc. is a research-based global biopharmaceutical company whose global portfolio includes medicines and vaccines. The company operates through two business segments: Pfizer Innovative Health (IH) that focus on develop and commercialize medicines and vaccines, Pfizer Essential Health (EH) that includes legacy brands, branded generics, generic sterile injectable products, biosimilars, and infusion systems.
About BioNTech
BioNTech is a next generation immunotherapy company that is involved in the development of novel therapies for the treatment of cancer and other serious diseases. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, which include Eli Lilly and Company, Bayer Animal Health, Genmab, Sanofi, Genentech, a member of the Roche Group, Genevant, Fosun, and Pfizer.
